论文部分内容阅读
肺炎球菌多糖苗苗不能预防婴儿中最常见的肺炎球菌感染,为此作者对肺炎球菌荚膜多糖-白喉类毒素结合菌苗(PncD)在幼婴中的免疫原性进行了研究.PncD是由4个型(6B、14、19F和23F)的肺炎球菌荚膜多糖与白喉类毒素共价结合构成的菌苗,白喉类毒素蛋白与6B、14、19F及23F型多糖之比分别为2.0、2.7、3.1和2.8.125名9～13周龄的健康婴儿被随机分为4组:PncD 01组(25人,每剂菌苗含每种多糖1μg)、PncD 03组(25人,每剂菌苗含每种多糖3μg)、PncD 10组(25人,每剂菌苗含每种多糖10μg)及安慰剂组(50人).所有婴儿分别于2、4、6月龄接受3剂PncD或安慰剂.14月龄时,PncD组的一半婴儿接受1剂PncD 03加强免疫,另一半则接受 1剂肺炎球菌多糖菌苗;安慰剂组给予1剂PncD 03.分别于每次免疫前及 7、15、24月龄时采血.用酶免疫测定(EIA)检测血样中的多糖抗体.
The pneumococcal polysaccharide vaccine failed to prevent the most common pneumococcal infection in infants and for this reason the authors investigated the immunogenicity of the pneumococcal capsular polysaccharide-diphtheria toxoid-conjugated vaccine (PncD) in young infants. Four strains (6B, 14, 19F and 23F) of pneumococcal capsular polysaccharide and diphtheria toxoid covalently bonded to the composition of the vaccine, diphtheria toxoid protein and 6B, 14, 19F and 23F polysaccharide ratio were 2.0, 2.7, 3.1 and 2.8.125 healthy infants aged 9-13 weeks were randomly assigned to 4 groups: PncD 01 group (25 individuals, each vaccine containing 1 μg of each polysaccharide), PncD 03 group (25 subjects, The vaccine contained 3 μg of each polysaccharide), PncD 10 (25, each vaccine containing 10 μg of each polysaccharide) and placebo (50) All infants received 3 doses of PncD at 2, 4 and 6 months Or placebo At 14 months of age, half of infants in the PncD group received one dose of PncD 03 booster immunization and the other half received one dose of pneumococcal vaccine, and the placebo group received one dose of PncD 03. In each group, Blood samples were taken at 7, 15 and 24 months of age, and polysaccharide antibodies in blood samples were detected by enzyme immunoassay (EIA).